On July 2, 2026 Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, reported that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the "Offering"). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of the Offering is expected to occur on or about July 6, 2026, subject to the satisfaction of customary closing conditions. Elicio intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, to primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and Elicio’s pipeline and platform, as well as for working capital and general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Titan Partners, a division of American Capital Partners, is acting as lead placement agent for the Offering. B. Riley Securities, Inc. is acting as co-placement agent for the Offering.

The Offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-293861) initially filed with the Securities and Exchange Commission ("SEC") on February 27, 2026, as amended on March 12, 2026, and declared effective by the SEC on March 16, 2026 (the "Registration Statement"). The shares of common stock are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to, and describing the terms of, the Offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and accompanying prospectus may also be obtained, when available, by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at [email protected], or B. Riley Securities, Inc. at 1655 Fort Myer Drive, Suite 1200, Arlington, Virginia 22209, Attention: Syndicate Prospectus Department, by telephone at 703-312-9580 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ELI-002

Elicio’s lead product candidate, ELI-002, is a structurally novel investigational AMP cancer immunotherapy that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio’s proprietary AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration.

ELI-002 7P (7-peptide formulation) was evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with mKRAS-driven pancreatic cancer (NCT05726864). The Phase 2 AMPLIFY-7P trial included patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. Based on topline results and post-hoc analyses, Elicio has refined its Phase 3 development strategy to focus on patients with lower residual disease burden and extended treatment duration. Elicio intends to initiate a Phase 1 study in metastatic PDAC designed to provide a rapid assessment of clinical activity through a focused, confirmatory study, subject to funding. Elicio plans to use the study findings to further evaluate checkpoint inhibitor combinations and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial. At the time of the Phase 2 AMPLIFY-7P analysis, data for overall survival remained immature. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in 25% of all solid tumors, thereby increasing the potential patient population for ELI-002.

(Press release, Elicio Therapeutics, JUL 2, 2026, View Source [SID1234669060])

On July 2, 2026 Nona Biosciences ("Nona"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, reported the appointment of Dr. Peng Wang as Chief Operating Officer (COO). Dr. Wang will be based in Suzhou and report directly to Dr. Di Hong, Chief Executive Officer of Nona Biosciences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this role, Dr. Wang will be responsible for establishing an efficient and integrated scientific research platform, rapidly building core technical capabilities, and upgrading the Company’s comprehensive and standardized scientific research service system. He will lead efforts to realize lean and efficient resource management, with a focus on elevating overall project management efficiency to support Nona’s growing portfolio of partner programs.

Dr. Wang brings over 15 years of extensive experience in biomedical research and drug development. Prior to joining Nona, he served as Head of Biologics and in vitro APAC at Crown Bioscience. Before that, he held the position of Head of Antibody Group at WuXi AppTec and served as a Senior Scientist at Roche. Dr. Wang began his career with several years of postdoctoral research experience at the University of Pennsylvania.

"We are very pleased to welcome Dr. Peng Wang to Nona Biosciences at a pivotal time as we continue to strengthen our platform capabilities and enhance our operational infrastructure," said Dr. Di Hong, Chief Executive Officer of Nona Biosciences. "Peng’s deep expertise across biologics development, antibody discovery, and research operations will be instrumental in formulating our long-term platform strategy and ensuring the efficient execution of our project portfolio. I am confident that he will fulfill his role to the best of his ability and maintain Nona’s high standard of performance and delivery."

"Nona Biosciences has established itself as a leader in antibody discovery and engineering, with its proprietary technology platforms and integrated I to I framework from idea to IND," said Dr. Peng Wang, Chief Operating Officer of Nona Biosciences. "I am excited to join the team and look forward to further enhancing our scientific capabilities, streamlining operations, and delivering greater value to our partners."

Dr. Wang holds a Ph.D. in Molecular Biology from the University of Delaware.

(Press release, Nona Biosciences, JUL 2, 2026, View Source [SID1234669062])

On July 2, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported that the first patient has been dosed in an investigator-initiated trial (IIT, NCT07319195) evaluating intratumoral administration of mitazalimab, Alligator’s lead CD40 agonist, in patients with early-stage breast cancer. The study will evaluate mitazalimab given as a single intratumoral dose, either alone or in combination with a single intratumoral dose of the PD-1 inhibitor nivolumab, prior to surgery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

While checkpoint inhibitors have improved outcomes in some breast cancer subtypes, there remains a need for more effective and better-tolerated immunotherapy approaches in others. In a recent publication in NPJ Breast Cancer, Dr Zhang has demonstrated that CD40 agonists synergize with PD-1 inhibitor in preclinical breast cancer models eradicating tumors and providing long lasting tumor immunity. This IIT will explore if local CD40 activation can enhance anti-tumor immunity in resectable breast cancer, and generate translational insights to guide further randomized trials.

The primary endpoints are safety and feasibility of administering mitazalimab, with or without nivolumab, prior to surgery. Secondary and exploratory objectives include pathologic and imaging-based measures of anti-tumor activity and translational analyses intended to characterize immune activation in the tumor microenvironment.

"We are pleased to support this investigator-initiated trial evaluating intratumoral mitazalimab in early-stage breast cancer. Breast cancer is the most common cancer in women, and the leading cause of cancer-related death. said Søren Bregenholt, CEO of Alligator Bioscience. As the biology and treatment of breast cancer varies significantly from that of pancreatic cancer this trial has the potential to generate valuable new translational insights that can guide future development to expand the clinical utility of mitazalimab."
About investigator-initiated trials
Investigator-initiated trials (IITs) are sponsored and executed by clinical investigators, with Alligator’s consent, but without our direct involvement besides supplying mitazalimab, providing scientific input and ensuring certain aspects of clinical safety reporting. IITs offer the opportunity to strengthen our understanding of mitazalimab’s mechanism of action, expand its potential use beyond pancreatic cancer, and explore additional indications to support further development. Alligator announces the initiation of an IIT once the first patient has been dosed with mitazalimab, and shares key outcomes and milestones, but does not commit to provide regular updates on individual trials.

(Press release, Alligator Bioscience, JUL 2, 2026, View Source [SID1234669050])

On July 2, 2026 LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) ("LIXTE" or the "Company") reported it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc. ("NOMAD"), a market leader in deployable, utility-grade battery energy storage systems (BESS), In connection with the merger, the Company is issuing to the NOMAD accredited stockholders 2,992,041 shares of its common stock and 50,366.07 shares of its newly authorized Series D preferred stock (which shares are convertible into 50,366,070 shares of NOMAD common stock on a 1 for 1,000 basis following the receipt of Company stockholder approval).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company also announced it has changed its corporate name to NOMAD Power Solutions, Inc. effective as of July 3, 2026, and its trading symbol to "NMAD" effective as of July 6, 2026.

"We are delighted to have completed this transaction, which transforms LIXTE into a new and exciting, rapidly growing sector, allowing us to address a multi-billion-dollar market and establish the foundation for a highly scalable infrastructure platform," said Geordan Pursglove, LIXTE’s Chief Executive Officer. "NOMAD instantly places us at the center of powerful long-term trends, including artificial intelligence, electrification, grid modernization and industrial expansion, including the massive power demands of the AI boom and the corporate push into pure-play deployable power."

As a result of the merger, NOMAD becomes a wholly owned subsidiary of the Company and will continue under the leadership of its CEO John Travaglini and his team. NOMAD is continuing to experience rapid growth in 2026. NOMAD is engaged on more than 30 active utility, infrastructure and strategic customer projects across North America.

"The demand we are experiencing across utility, AI infrastructure and industrial markets confirms that deployable BESS has become an essential layer of the modern grid," Travaglini said. "Becoming a part of a publicly traded company through LIXTE provides us with the capital and public-market visibility to scale manufacturing, deepen our customer relationships, continue defining the category we created and scale our growth.

"As AI workloads and data center buildout accelerate power consumption at an unprecedented pace, grid infrastructure cannot absorb that demand through traditional fixed assets alone. Our ability to rapidly deploy megawatt-scale storage anywhere, essentially eliminating siting delays, construction permitting burdens, and the capital lock-up of traditional installations, gives us a competitive advantage and represents a sea-change in the broad energy industry," Travaglini added.

(Press release, Nomad Power Solutions, JUL 2, 2026, View Source [SID1234670406])

On July 2, 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) reported positive results from the phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS G12C inhibitor, against the approved, first generation KRAS G12C inhibitors sotorasib or adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC). The study met its primary and key secondary endpoint, with divarasib achieving clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival (OS). The safety profile for divarasib remained consistent with previous data, with no new findings detected and the most common treatment-related events being manageable and reversible.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The superior survival demonstrated in this global head-to-head comparison of KRAS G12C inhibitors confirms the potential of divarasib to improve clinical outcomes for people with KRAS G12C non-small cell lung cancer," said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. "These results should establish divarasib as a new standard of care for previously-treated lung cancer patients with this genetically defined tumor subtype."

Efficacious treatments for KRAS G12C NSCLC represent a significant unmet need in lung cancer care. The G12C mutation is one of the most common KRAS oncogene mutations, found in approximately 14% of NSCLC cases and associated with poor prognosis for patients.1,2

Roche is advancing a comprehensive phase III clinical development programme in NSCLC, investigating divarasib as both a monotherapy and as a chemotherapy-free combination, across different disease settings and lines of therapy. The US Food and Drug Administration granted Breakthrough Therapy Designation to divarasib in 2022, and in 2026, Orphan Drug Designation for KRAS G12C non-small cell lung cancer (NSCLC).

Data from the Krascendo 1 study will be presented at an upcoming medical meeting and submitted to health authorities with the aim of bringing this potential treatment option to people with KRAS G12C NSCLC as soon as possible.

About Krascendo 1
The Krascendo 1 study [NCT06497556] is the only global head-to-head study evaluating a Kirsten rat sarcoma virus (KRAS) G12C inhibitor in direct comparison with first generation KRAS G12C inhibitors.3 This phase III, randomised, open-label, multicentre study evaluates the efficacy and safety of divarasib monotherapy versus sotorasib or adagrasib in people with previously treated KRAS G12C-mutant advanced or metastatic non-small cell lung cancer.3 The study includes 338 adults, randomised to receive either divarasib (once daily) or, either sotorasib (once daily) or adagrasib (twice daily).3 The primary endpoint is blinded independent central review (BICR)-assessed progression-free survival.3 Secondary endpoint measures include overall survival, confirmed objective response, duration of response, as well as other efficacy and safety measures.3

About divarasib
Divarasib is an investigational, next-generation, oral, KRAS G12C inhibitor. It has shown greater potency and selectivity in preclinical studies compared with first generation KRAS G12C-targeting treatments, sotorasib and adagrasib.4,5 Divarasib is designed to selectively bind to the KRAS G12C protein, locking the protein in an inactive (‘off’) state, thereby turning off its tumour-driving signalling.6

Divarasib’s comprehensive clinical development programme is anchored by three phase III studies:

Study Intervention Patient population
Krascendo 1
[NCT06497556] Divarasib monotherapy vs sotorasib or adagrasib Previously treated KRAS G12C-mutant advanced or metastatic NSCLC (second-line)
Krascendo 2
[NCT06793215] Divarasib plus pembrolizumab
(chemotherapy-free combination) vs chemotherapy plus pembrolizumab Previously untreated KRAS G12C-mutant advanced NSCLC (first-line)
Krascendo 3
[NCT07541170] Adjuvant divarasib monotherapy vs immunotherapy or observation Resected stage II–IIIB KRAS G12C-mutant NSCLC after standard of care chemoimmunotherapy (early-stage)
About KRAS G12C non-small cell lung cancer
Despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths worldwide, surpassing the combined mortality rates of breast, prostate, and stomach cancers.7,8 Each year, it claims the lives of 1.8 million people, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases.7,9 KRAS is one of the most frequently mutated genes in lung cancer, occurring in approximately 25% of newly diagnosed lung cancers.10 The G12C mutation is one of the most common KRAS mutations, found in approximately 14% of NSCLC cases.1

The KRAS gene produces the KRAS protein, which acts as a cellular control switch, cycling between an active (‘on’) and inactive (‘off’) state to regulate cell growth and proliferation, making it a critical target for new therapeutic strategies.10 The G12C mutation locks the KRAS protein in its active (‘on’) state, leading to continuous, unregulated signalling for cell growth, driving tumour proliferation.

(Press release, Hoffmann-La Roche, JUL 2, 2026, View Source [SID1234669051])